Tetra Bio Pharma Inc TBPMQ

Healthcare Cannabis

Tetra Bio-Pharma Inc. is a Canada-based cannabinoid-derived drug discovery and development company. The Company has developed a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. The Company has a pipeline of formulations and drug delivery systems with a portfolio of assets from the early research and development phase to advanced stage clinical programs. Its products include QIXLEEF, CAUMZ, PPP004, REDUVO, and REBORN 1. QIXLEEF is a botanical therapy with a fixed dosage of tetrahydrocannabinol (THC) and cannabidiol (CBD). CAUMZ is its inhaled cannabinoid-derived drug candidate. PPP004 is a topical preparation containing either a standardized amount of CBD or a defined ratio of THC and CBD. REDUVO is a soft gel capsule used to treat chemotherapy-induced nausea and vomiting (CINV) and weight loss and severe nausea in people living with human immunodeficiency virus (HIV) infection. REBORN 1 is in phase II trial.

GREY:TBPMQ - Post by User

Tetra Bio Pharma Inc > QIXLEEF

<< Previous

Bullboard Posts

Next >>

Post by Golddetectoron Jan 23, 2022 10:49am

201 Views

Post# 34349739

QIXLEEF

We are at phaseII FDA (reborn trial) projected to conclude Q1 fda thumb up to follow shortly. Imo big pharma will take over from there. If you check most of take overs are at that stage. Tetra has to play this carefully. Sp is too low for a take over. This needs to be at least 1$ to get something meaningful to shareholders. Let's keep in mind this was above 1$ before covid and they did not advance the trials at that time. All this value added is not captured in sp. the following weeks in q1 and q2 will be interesting

<< Previous

Bullboard Posts

Next >>

Investors eye Australian gold mining projects amid promising developments